Efficacy of the Dupilumab 200 Mg Dose Every 2 Weeks in Children with Moderate-to-Severe Asthma during Voyage and Excursion

Author(s)

Phipatanakul W1, Vogelberg C2, Bacharier LB3, Dell SD4, Altincatal A5, Gall R6, Ledanois O7, Sacks H6, Jacob-Nara JA8, Deniz Y6, Rowe PJ8
1Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, 2University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany, 3Monroe Carell Jr Children’s Hospital at Vanderbilt University Medical Center, Nashville, TN, USA, 4BC Children’s Hospital, Vancouver, BC, Canada, 5Sanofi, Cambridge, MA, USA, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 7Sanofi, Paris, France, 8Sanofi, Bridgewater, NJ, USA

OBJECTIVES: In VOYAGE (NCT02948959), 6–11-year-old children with uncontrolled, moderate-to-severe asthma received dupilumab 100mg q2w (body weight ≤30kg at baseline) or 200mg q2w (>30kg at baseline) for 52 weeks. In the 52-week open-label extension EXCURSION study (NCT03560466), children (>30kg) received dupilumab 200mg q2w. Dupilumab reduced exacerbation rates (AER), improved percent-predicted FEV1 and was generally well tolerated. Pharmacokinetic/pharmacodynamic VOYAGE data showed comparable dose exposure between both regimens. This analysis assessed whether dupilumab 200mg q2w efficacy is comparable with the overall analysis.

METHODS: This post hoc analysis of VOYAGE and EXCURSION includes children who received dupilumab 200mg or placebo q2w for 52 weeks in VOYAGE and dupilumab 200mg q2w for 52 weeks in EXCURSION, although the study was not powered to assess efficacy with this dose separately. Endpoints: unadjusted AER; change from VOYAGE baseline in ppFEV1 at Weeks 12 and 52.

RESULTS: Of 408 children, 158 received dupilumab 200mg q2w in both VOYAGE and EXCURSION (dupilumab/dupilumab), 105 children received placebo in VOYAGE and dupilumab 200mg q2w in EXCURSION (placebo/dupilumab). In VOYAGE, unadjusted AER was lower in dupilumab vs placebo groups (0.392 vs 0.608). In EXCURSION, further reductions were observed (0.129 dupilumab/dupilumab, 0.136 placebo/dupilumab). In VOYAGE, dupilumab improved ppFEV1 at Week 12 by mean (SD) of 11.3 (16.4) percentage points, and 13.2 (18.4) points by Week 52; in the placebo arm, marginal improvements were observed at Week 12 (3.5 [11.4] percentage points) and Week 52 (2.6 [13.6] points). In EXCURSION, dupilumab sustained improvements in ppFEV1 in the dupilumab/dupilumab arm (change from VOYAGE baseline at Week 12: 10.9 [17.7]; Week 52: 12.2 [17.8] percentage points) and improved ppFEV1 in the placebo/dupilumab arm (Week 12: 7.2 [13.6] percentage points), sustained to Week 52 (7.6 [16.1] points).

CONCLUSIONS: In patients >30 kg, the dupilumab 200mg dose achieved effective asthma control, in children with uncontrolled, moderate-to-severe asthma.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

CO26

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment

Disease

Biologics & Biosimilars, Pediatrics

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×